Data-Driven Decisions in Crohn's Disease: Positioning Patients for SuccessPremiere Date: Monday, October 25, 2021
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, October 25, 2022
Note: Credit Is No Longer Available
|David T. Rubin, MD (Moderator)
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
|Oriana M. Damas, MD
Assistant Professor of Medicine
Director of Translational Studies for the Crohn's and Colitis Center
Division of Gastroenterology, Department of Medicine
University of Miami Miller School of Medicine
|Millie D. Long, MD, MPH
Professor of Medicine
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, NC
|Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Digestive Disease and Surgery
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Professor, Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
While there is a tendency for clinicians to rely on one approach to treating Crohn's disease (CD), making confident data-driven treatment decisions in moderate-to-severe CD is imperative for durable, long-term remission. The traditional approach that has been based on progressive, step-wise treatment intensification with re-evaluation of response according to symptoms does not improve long-term outcomes in CD and increases risk for bowel damage. However, the introduction of treat-to-target (T2T) management strategies and the integration of novel therapies targeting new pathways supported by long-term efficacy and safety data have resulted in a paradigm shift in CD treatment.
This unique symposium will harness the experience, evidence, and expertise of team leaders in the management of CD to offer new insights and strategies to optimize treatment positioning. A patient case will serve as the foundation and springboard for solving complex clinical conundrums of patients with CD seen daily in practice.
At the end of this CE activity, participants should be able to:
- Incorporate individual disease characteristics into treatment decisions in CD based on evidence-based recommendations.
- Differentiate biologic therapies in CD based on efficacy and long-term safety to achieve a rapid and durable treatment response.
- Develop a data-driven treatment algorithm for CD to position treatment choices based on efficacy, safety, and patient characteristics.
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Gastroenterologists, primary care physicians, nurse practitioners, PAs, nurses, and pharmacists
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Rubin reports that he receives grants from Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Arena Pharmaceuticals, Inc.; Bellatrix Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol Myers Squibb Company; CDx Diagnostics; Celgene Corporation/Syneos Health; Check-Cap; Dizal Pharmaceutical; Eli Lilly and Company; GalenPharma/Atlantica; Genentech, Inc./Roche; Gilead Sciences, Inc.; Ichnos Sciences SA; InDex Pharmaceuticals; Iterative Scopes, Inc.; Janssen Pharmaceuticals, Inc.; Materia Prima; Narrow River Management; Pfizer Inc.; Prometheus Laboratories Inc.; Reistone Biopharma; Takeda Pharmaceuticals U.S.A., Inc.; and Techlab, Inc. He has other financial interest in or material support as Co-Founder, CFO of Cornerstones Health, Inc. (non-profit).
Dr. Damas reports she receives grants from Pfizer Inc. She receives research support from National Institutes of Health (NIH NIDDK K23 Award) and Pfizer Inc.
Dr. Long reports that she receives grants and research support from Pfizer Inc. She consults for AbbVie Inc.; Bristol Myers Squibb Company; Calibr; Eli Lilly and Company; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Roche; Takeda Pharmaceuticals U.S.A., Inc.; TARGET PharmaSolutions, Inc.; and Theravance Biopharma.
Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on advisory boards and consults for AbbVie Inc.; Alfasigma, S.p.A; Allergan; Amgen Inc.; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Miraca Laboratories; Pfizer Inc.; Prometheus Biosciences; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; TARGET PharmaSolutions, Inc.; and UCB, Inc.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).